Cellect Biotechnology Ltd. Form 6-K Summary
Business Context and Reporting Period
This Form 6-K was filed by Cellect Biotechnology Ltd., a foreign private issuer based in Kfar Saba, Israel, for the month of January 2020. The filing serves to disclose a material corporate event announced via press release on January 8, 2020.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, or margin data. The primary financial metric disclosed is the pricing of a $3 million registered direct offering of American Depositary Shares (ADS).
Material Changes
The material change reported is the execution of a capital raise. Cellect Biotechnology Ltd. priced a registered direct offering totaling $3 million. No comparative financial data or changes in operating metrics versus prior periods are included in this specific filing.
Guidance, Outlook, and Risks
The filing incorporates a press release regarding the offering but does not contain updated financial guidance, management commentary on future operations, or a discussion of specific risks and contingencies beyond the context of the capital raise. The filing does not provide a clear value for any unusual items outside of the offering itself.
Investor Verification Checklist
- Verify the final closing date and actual proceeds received from the $3 million registered direct offering.
- Confirm the number of American Depositary Shares issued and the specific price per share.
- Review the use of proceeds disclosed in the full press release (Exhibit 99.1) to understand capital allocation.
- Check for any dilution impact on existing shareholders resulting from this offering.